ACHN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACHN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Achillion Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2019 was $-78.33 Mil. Achillion Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2019 was $242.36 Mil. Therefore, Achillion Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2019 was -32.32%.
The historical rank and industry rank for Achillion Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
The historical data trend for Achillion Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achillion Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -43.23 | -1.62 | -14.05 | -22.68 | -22.84 |
Achillion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -21.47 | -23.42 | -28.06 | -30.41 | -32.32 |
For the Biotechnology subindustry, Achillion Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Achillion Pharmaceuticals's Return-on-Tangible-Asset falls into.
Achillion Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2018 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2018 ) | (A: Dec. 2017 ) | (A: Dec. 2018 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2018 ) | (A: Dec. 2017 ) | (A: Dec. 2018 ) | |||||
= | -70.272 | / | ( (337.613 | + | 277.858) | / 2 ) | |
= | -70.272 | / | 307.7355 | ||||
= | -22.84 % |
Achillion Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2019 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Sep. 2019 ) | (Q: Jun. 2019 ) | (Q: Sep. 2019 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Sep. 2019 ) | (Q: Jun. 2019 ) | (Q: Sep. 2019 ) | |||||
= | -78.332 | / | ( (248.375 | + | 236.342) | / 2 ) | |
= | -78.332 | / | 242.3585 | ||||
= | -32.32 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2019) net income data.
Achillion Pharmaceuticals (NAS:ACHN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph Truitt | director, officer: Chief Executive Officer | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Kurt Graves | director | C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Michael D Kishbauch | director | 18 CHERRYVILLE RD, FLEMINGTON NJ 08822 |
Jason S Fisherman | director | C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Nicole Vitullo | director | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Martha E Manning | officer: General Counsel | 700 PENNSYLVANIA DR, EXTON PA 19341 |
Frank Verwiel | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Paul E Firuta | officer: EVP, Chief Commercial Officer | 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921 |
Steven Zelenkofske | officer: EVP, Chief Medical Officer | 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920 |
Mary Kay Fenton | officer: Chief Financial Officer | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Milind Deshpande | director, officer: Chief Executive Officer | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Johnson & Johnson Innovation - Jjdc, Inc. | 10 percent owner | 410 GEORGE STREET, NEW BRUNSWICK NJ 08901 |
Johnson & Johnson | 10 percent owner | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933 |
David Apelian | officer: Chief Medical Officer | C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511 |
From GuruFocus
By Marketwired Marketwired • 08-30-2019
By PRNewswire PRNewswire • 10-17-2019
By Marketwired Marketwired • 05-09-2019
By Marketwired Marketwired • 12-09-2019
By Marketwired Marketwired • 04-03-2019
By Marketwired Marketwired • 11-11-2019
By PRNewswire PRNewswire • 10-19-2019
By PRNewswire PRNewswire • 10-16-2019
By Marketwired Marketwired • 03-08-2019
By Marketwired Marketwired • 05-17-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.